{"metadata": {"source": "psychonaut_CSV", "row": 23, "doc_id": "doc_252", "num_chunks": 39, "chunk_id": "252::chunk_30", "document_index": 252, "latency_s": 0.6855777000018861, "prompt_toks": 6555, "completion_toks": 77, "relevance_score": 1.18860825e-07}, "content": "Drug: Unknown | cid: N/A\nSource: psychonaut_CSV | Source description: ?\n\n                    Text: \n                    breath is slowed down mildly to moderately, but does not cause noticeable impairment. At high doses and overdoses, opioid-induced respiratory depression can result in a shortness of breath, abnormal breathing patterns, semi-consciousness, or unconsciousness. Severe overdoses can result in a coma or death without immediate medical attention. Sedation - At higher dosages, this compound can result in feelings of sedation and is considerably more sedating than that of oxycodone and hydrocodone . Appetite suppression Constipation Cough suppression Decreased libido Difficulty urinating Nausea - This effect is more likely to occur during high dosages and/or when the user doesn't adequately pace themselves. Orgasm suppression Pupil constriction\n\n\n                    Context: \n                    This excerpt summarizes the physical effects and risks associated with codeine use, including respiratory depression, sedation, and common side effects like nausea, constipation, and sexual effects. It highlights the dose-dependent nature of respiratory impairment and sedation, emphasizing the importance of responsible dosing. This information is crucial for understanding codeine’s pharmacological profile and safety considerations within the comprehensive drug profile.\n                "}
{"metadata": {"source": "erowid", "title": "Erowid Buprenorphine (Temgesic, Subutex) Vault : Drug Testing", "description": "Information about Buprenorphine (Temgesic, Subutex) and drug testing", "language": "No language found.", "url": "https://www.erowid.org/pharms/buprenorphine/buprenorphine_testing.shtml", "drug": "Buprenorphine", "cid": 644073, "substance": "buprenorphine", "category": "PHARMS", "erowid_column": "Testing", "char_count": 5401, "word_count": 775, "doc_id": "doc_120", "num_chunks": 7, "chunk_id": "120::chunk_5", "document_index": 120, "latency_s": 0.9721411000064109, "prompt_toks": 1726, "completion_toks": 95, "relevance_score": 6.615601e-08}, "content": "Drug: Buprenorphine | cid: 644073\nSource: erowid | Source description: Information about Buprenorphine (Temgesic, Subutex) and drug testing\nErowid name: buprenorphine\nCategory: PHARMS\nField: Testing\n\n                    Text: \n                    Buprenorphine does not cause a positive result in a standard opiate urine quick test (stick, cup, etc). Many opiate tests test only for morphine (which both codeine and heroin break down into). This is true for both home/business kits and laboratory testing. Because buprenorphine does not break down into morphine, it is therefore not detected by these tests. Home and laboratory testing is available that will detect buprenorphine. Test results depend on the specific test that is used and whether or not laboratory verification is required. When drug testing is being conducted on known opioid users, specific buprenorphine testing is sometimes used to verify that it is not being used. Because buprenorphine has become more popular among prisoners and opioid addicts since the mid 2000s, there are more labs that look for buprenorphine and more groups that have added it to their list of substances identified. When urine samples are sent for lab confirmation, buprenorphine is usually detected.\n\n\n                    Context: \n                    This excerpt provides detailed information about drug testing for buprenorphine, explaining its detection in urine tests, differences from other opiates like morphine, and its increasing presence in laboratory screenings since the mid-2000s. It is relevant within the broader context of the Erowid Pharmaceuticals Vault, which covers various drugs and drug testing methods. The details about detection times, test types, and lab verification are critical for understanding buprenorphine's detection profile.\n                "}
{"metadata": {"source": "erowid", "title": "Erowid Ketamine Vault : Health", "description": "Information on health affects and concerns related to Ketamine.", "language": "No language found.", "url": "https://www.erowid.org/chemicals/ketamine/ketamine_health.shtml", "drug": "Ketamine", "cid": 3821, "substance": "ketamine", "category": "CHEMICALS", "erowid_column": "Health", "char_count": 11594, "word_count": 1705, "doc_id": "doc_145", "num_chunks": 15, "chunk_id": "145::chunk_5", "document_index": 145, "latency_s": 0.6486846000043442, "prompt_toks": 3074, "completion_toks": 73, "relevance_score": 5.7477344e-08}, "content": "Drug: Ketamine | cid: 3821\nSource: erowid | Source description: Information on health affects and concerns related to Ketamine.\nErowid name: ketamine\nCategory: CHEMICALS\nField: Health\n\n                    Text: \n                    people use nitrous oxide during ketamine's onset and comedown periods. Effects Unpracticed trippers may be somewhat overwhelmed by the effects of stronger doses, although in general fear that may come up is likely to be only episodic (unlike LSD trip and other drug paranoias). Food should not be consumed within an hour and a half before the trip, and should be avoided for longer periods of time if possible. Nausea is likely and more pronounced when users try to get up and move around within the first 90 minutes after injection. A peculiar sort of loneliness can occur, so many people prefer to be with people they are close to. It is best to have a sober monitor or experienced user at hand. Habituation & Addiction Some people with a steady supply or a large quantity of ketamine encounter problems with habituation. One ketamine user recommends that people set a limit on use *before* ever trying it so they can have a benchmark against which to judge usage levels. Write down the limits.\n\n\n                    Context: \n                    This section discusses the effects and safety considerations of combining nitrous oxide with ketamine use, emphasizing potential experiences during onset and comedown, the importance of having a sober monitor, and strategies to manage habituation and addiction risks. It provides practical advice on minimizing adverse effects and establishing usage limits, contributing to the overall health and safety information on ketamine in the document.\n                "}
